ELEVANCE HEALTH INC (A58.DE) Fundamental Analysis & Valuation

FRA:A58 • US0367521038

Current stock price

253.2 EUR
-2.3 (-0.9%)
Last:

This A58.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. A58.DE Profitability Analysis

1.1 Basic Checks

  • In the past year A58 was profitable.
  • In the past year A58 had a positive cash flow from operations.
  • In the past 5 years A58 has always been profitable.
  • In the past 5 years A58 always reported a positive cash flow from operatings.
A58.DE Yearly Net Income VS EBIT VS OCF VS FCFA58.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

1.2 Ratios

  • With an excellent Return On Assets value of 4.66%, A58 belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
  • A58 has a Return On Equity of 12.90%. This is amongst the best in the industry. A58 outperforms 81.82% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 5.74%, A58 is in line with its industry, outperforming 57.58% of the companies in the same industry.
  • A58 had an Average Return On Invested Capital over the past 3 years of 6.74%. This is in line with the industry average of 5.88%.
Industry RankSector Rank
ROA 4.66%
ROE 12.9%
ROIC 5.74%
ROA(3y)5.09%
ROA(5y)5.45%
ROE(3y)14.2%
ROE(5y)15.16%
ROIC(3y)6.74%
ROIC(5y)7.11%
A58.DE Yearly ROA, ROE, ROICA58.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • Looking at the Profit Margin, with a value of 2.84%, A58 is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
  • A58's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 4.07%, A58 is in line with its industry, outperforming 42.42% of the companies in the same industry.
  • In the last couple of years the Operating Margin of A58 has declined.
Industry RankSector Rank
OM 4.07%
PM (TTM) 2.84%
GM N/A
OM growth 3Y-9.09%
OM growth 5Y-8.43%
PM growth 3Y-8.92%
PM growth 5Y-5.39%
GM growth 3YN/A
GM growth 5YN/A
A58.DE Yearly Profit, Operating, Gross MarginsA58.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. A58.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), A58 is destroying value.
  • Compared to 1 year ago, A58 has less shares outstanding
  • The number of shares outstanding for A58 has been reduced compared to 5 years ago.
  • Compared to 1 year ago, A58 has an improved debt to assets ratio.
A58.DE Yearly Shares OutstandingA58.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
A58.DE Yearly Total Debt VS Total AssetsA58.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • The Debt to FCF ratio of A58 is 10.10, which is on the high side as it means it would take A58, 10.10 years of fcf income to pay off all of its debts.
  • A58's Debt to FCF ratio of 10.10 is in line compared to the rest of the industry. A58 outperforms 48.48% of its industry peers.
  • A Debt/Equity ratio of 0.71 indicates that A58 is somewhat dependend on debt financing.
  • A58 has a Debt to Equity ratio of 0.71. This is in the better half of the industry: A58 outperforms 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 10.1
Altman-Z N/A
ROIC/WACC0.73
WACC7.91%
A58.DE Yearly LT Debt VS Equity VS FCFA58.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
A58.DE Yearly Current Assets VS Current LiabilitesA58.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. A58.DE Growth Analysis

3.1 Past

  • A58 shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.49%.
  • A58 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.12% yearly.
  • The Revenue has grown by 12.62% in the past year. This is quite good.
  • A58 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.32% yearly.
EPS 1Y (TTM)-8.49%
EPS 3Y1.27%
EPS 5Y6.12%
EPS Q2Q%-13.28%
Revenue 1Y (TTM)12.62%
Revenue growth 3Y8.34%
Revenue growth 5Y10.32%
Sales Q2Q%8.51%

3.2 Future

  • A58 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.55% yearly.
  • A58 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.69% yearly.
EPS Next Y-13.31%
EPS Next 2Y-1.08%
EPS Next 3Y4.72%
EPS Next 5Y8.55%
Revenue Next Year-2.72%
Revenue Next 2Y0.09%
Revenue Next 3Y1.74%
Revenue Next 5Y2.69%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
A58.DE Yearly Revenue VS EstimatesA58.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50B 100B 150B 200B
A58.DE Yearly EPS VS EstimatesA58.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30 40 50

More info and screens

Find the best growth stocksShow best growing peers

4

4. A58.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.70, the valuation of A58 can be described as reasonable.
  • A58's Price/Earnings ratio is rather cheap when compared to the industry. A58 is cheaper than 90.91% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of A58 to the average of the S&P500 Index (25.23), we can say A58 is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 11.19, the valuation of A58 can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, A58 is valued a bit cheaper than 75.76% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.42. A58 is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 9.7
Fwd PE 11.19
A58.DE Price Earnings VS Forward Price EarningsA58.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • A58's Enterprise Value to EBITDA ratio is in line with the industry average.
  • 60.61% of the companies in the same industry are cheaper than A58, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 20.34
EV/EBITDA 9.01
A58.DE Per share dataA58.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 200 400 600

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.59
EPS Next 2Y-1.08%
EPS Next 3Y4.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. A58.DE Dividend Analysis

5.1 Amount

  • A58 has a Yearly Dividend Yield of 2.36%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 1.96, A58 pays a bit more dividend than its industry peers.
  • A58's Dividend Yield is a higher than the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 2.36%

5.2 History

  • On average, the dividend of A58 grows each year by 12.23%, which is quite nice.
Dividend Growth(5Y)12.23%
Div Incr Years0
Div Non Decr Years0
A58.DE Yearly Dividends per shareA58.DE Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2025 2026 1 2 3 4 5

5.3 Sustainability

  • 27.00% of the earnings are spent on dividend by A58. This is a low number and sustainable payout ratio.
  • A58's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP27%
EPS Next 2Y-1.08%
EPS Next 3Y4.72%
A58.DE Yearly Income VS Free CF VS DividendA58.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
A58.DE Dividend Payout.A58.DE Dividend Payout, showing the Payout Ratio.A58.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

A58.DE Fundamentals: All Metrics, Ratios and Statistics

ELEVANCE HEALTH INC

FRA:A58 (3/20/2026, 7:00:00 PM)

253.2

-2.3 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)01-28
Earnings (Next)04-20
Inst Owners93.57%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap55.88B
Revenue(TTM)199.13B
Net Income(TTM)5.66B
Analysts74.29
Price Target338.62 (33.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.36%
Yearly Dividend5.9
Dividend Growth(5Y)12.23%
DP27%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.74%
Min EPS beat(2)6.46%
Max EPS beat(2)21.02%
EPS beat(4)3
Avg EPS beat(4)7.33%
Min EPS beat(4)-2.26%
Max EPS beat(4)21.02%
EPS beat(8)6
Avg EPS beat(8)1.93%
EPS beat(12)9
Avg EPS beat(12)1.87%
EPS beat(16)12
Avg EPS beat(16)2.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-2%
Max Revenue beat(2)0.45%
Revenue beat(4)3
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-2%
Max Revenue beat(4)4.3%
Revenue beat(8)6
Avg Revenue beat(8)0.85%
Revenue beat(12)9
Avg Revenue beat(12)1.1%
Revenue beat(16)12
Avg Revenue beat(16)0.96%
PT rev (1m)0%
PT rev (3m)-0.26%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)3.39%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)-4.23%
Revenue NQ rev (1m)-0.62%
Revenue NQ rev (3m)-5.04%
Revenue NY rev (1m)-0.39%
Revenue NY rev (3m)-5.97%
Valuation
Industry RankSector Rank
PE 9.7
Fwd PE 11.19
P/S 0.32
P/FCF 20.34
P/OCF 15.05
P/B 1.47
P/tB 14.88
EV/EBITDA 9.01
EPS(TTM)26.11
EY10.31%
EPS(NY)22.63
Fwd EY8.94%
FCF(TTM)12.45
FCFY4.92%
OCF(TTM)16.82
OCFY6.64%
SpS780.82
BVpS172.07
TBVpS17.01
PEG (NY)N/A
PEG (5Y)1.59
Graham Number317.95
Profitability
Industry RankSector Rank
ROA 4.66%
ROE 12.9%
ROCE 7.18%
ROIC 5.74%
ROICexc 6.26%
ROICexgc 11.5%
OM 4.07%
PM (TTM) 2.84%
GM N/A
FCFM 1.59%
ROA(3y)5.09%
ROA(5y)5.45%
ROE(3y)14.2%
ROE(5y)15.16%
ROIC(3y)6.74%
ROIC(5y)7.11%
ROICexc(3y)7.29%
ROICexc(5y)7.65%
ROICexgc(3y)13.44%
ROICexgc(5y)14.29%
ROCE(3y)8.45%
ROCE(5y)8.91%
ROICexgc growth 3Y-7.91%
ROICexgc growth 5Y-6.83%
ROICexc growth 3Y-6.71%
ROICexc growth 5Y-5.47%
OM growth 3Y-9.09%
OM growth 5Y-8.43%
PM growth 3Y-8.92%
PM growth 5Y-5.39%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.64
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 10.1
Debt/EBITDA 3.2
Cap/Depr 72.19%
Cap/Sales 0.56%
Interest Coverage 5.75
Cash Conversion 44.42%
Profit Quality 56.06%
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score5
WACC7.91%
ROIC/WACC0.73
Cap/Depr(3y)78.87%
Cap/Depr(5y)77.78%
Cap/Sales(3y)0.68%
Cap/Sales(5y)0.71%
Profit Quality(3y)81.36%
Profit Quality(5y)97.25%
High Growth Momentum
Growth
EPS 1Y (TTM)-8.49%
EPS 3Y1.27%
EPS 5Y6.12%
EPS Q2Q%-13.28%
EPS Next Y-13.31%
EPS Next 2Y-1.08%
EPS Next 3Y4.72%
EPS Next 5Y8.55%
Revenue 1Y (TTM)12.62%
Revenue growth 3Y8.34%
Revenue growth 5Y10.32%
Sales Q2Q%8.51%
Revenue Next Year-2.72%
Revenue Next 2Y0.09%
Revenue Next 3Y1.74%
Revenue Next 5Y2.69%
EBIT growth 1Y-11.4%
EBIT growth 3Y-1.51%
EBIT growth 5Y1.02%
EBIT Next Year-3.32%
EBIT Next 3Y3.47%
EBIT Next 5Y6.59%
FCF growth 1Y-29.25%
FCF growth 3Y-24.06%
FCF growth 5Y-19.97%
OCF growth 1Y-25.29%
OCF growth 3Y-20.06%
OCF growth 5Y-16.69%

ELEVANCE HEALTH INC / A58.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ELEVANCE HEALTH INC?

ChartMill assigns a fundamental rating of 4 / 10 to A58.DE.


What is the valuation status of ELEVANCE HEALTH INC (A58.DE) stock?

ChartMill assigns a valuation rating of 4 / 10 to ELEVANCE HEALTH INC (A58.DE). This can be considered as Fairly Valued.


What is the profitability of A58 stock?

ELEVANCE HEALTH INC (A58.DE) has a profitability rating of 5 / 10.


Can you provide the expected EPS growth for A58 stock?

The Earnings per Share (EPS) of ELEVANCE HEALTH INC (A58.DE) is expected to decline by -13.31% in the next year.


Is the dividend of ELEVANCE HEALTH INC sustainable?

The dividend rating of ELEVANCE HEALTH INC (A58.DE) is 5 / 10 and the dividend payout ratio is 27%.